Pharmacokinetic analysis and antiepileptic activity of two new isomers of N-valproyl glycinamide

Biopharmaceutics and Drug Disposition

Volumn 18, Issue 7, 1997, Pages 557-566

  Hadad, Salim ^a   Bialer, Meir ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Antiepileptic activity; Isomers; Pharmacokinetics; Valproyl glycinamide

Indexed keywords

ANTICONVULSIVE AGENT;

ANIMAL EXPERIMENT; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; INTRAVENOUS DRUG ADMINISTRATION; ISOMER; NEUROTOXICITY; NONHUMAN; PHARMACODYNAMICS; SEIZURE;

ANIMALS; ANTICONVULSANTS; DOGS; DRUG EVALUATION, PRECLINICAL; EPILEPSY; GLYCINE; HALF-LIFE; INJECTIONS, INTRAVENOUS; ISOMERISM; MICE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0030819103     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1099-081X(199710)18:7<557::AID-BDD48>3.0.CO;2-D     Document Type: Article

References (27)

1. B. S. Meldrum. Epilepsy and γ-aminobutyric acid-mediated inhibition. Int. Rev Neurobiol., 17. 1-36 (1975).
2. E. Roberts, T. N. Chase and D. B. Tower (Eds), GABA in Nervous System Function, Raven. New York, 1976.
3. M. J. Jung and M. G. Plafreyman, Vigabatrin- mechanism of action. In Antiepilepiic Drugs. 4th edn, R. H. Levy, R. H. Mattson and B. S. Meldrum (Eds). Raven, New York, 1995, pp. 903-914 and other chapters therein.
4. C. P. Taylor, Gabapentin - mechanism of action. In Antiepileptic Drugs, 4th edn, R. H. Levy, R. H. Mattson and B. S. Meldrum (Eds), Raven, New York. 1995, pp. 829-842 and other chapters therein.
5. J. Roba, R. Cavalier, A. Cordi, H. Gorissen, M. Herin, P. Janssens de Varebekc, P. C. Onkelinx, M. Remacle, W. van Dorsser, Milacemide. In New Anticonvulsant Drugs, B. S. Meldrum and R. J. Porter (Eds), Libby, London, 1986. pp. 179-190.
6. D. M. Lambert, J. H. Poupaert. J.-M Maloteaux. P. Dumont, Anticonvulsant activities of Nbenzyloxycarbonylglycine after parenteral administration Neuropharmacol. Neurorep., 5. 777-780(1994).
7. J. Liu. N. Seiler, C. Marescaux, A. Depauhs and M. Vergns, Potentiation of γ-vinyl GABA (vitabatrin) effects by glycine. Eur. J. Pharmacnl., 182, 109-115 (1990).
8. E. Toth and A. Lajtha, Glycine potentiates the action of some anticonvulsant drugs in some seizure models. Neurochem. Res., 8, 1711-1718 (1984).
9. J. D. Wood, P. Krogsgaard-Larscn and A. Schousboc. Amplification of glycine of the effect of GABA transport inhibitor. Neurochem. Res., 13. 917-921 (1988).
10. N. Seiler and S. Sarhan, Synergistic anticonvulsant effects of a GABA agonist and glycine. Gen. Pharmacol., 15, 367-369 (1984).
11. S. Hadad and M. Bialer. Pharmacokinetic analysis and anticpileptic activity of N-valproyl derivatives of GABA and glycine. Pharm. Rex., 12. 905-916 (1995)
12. G. Zaccara, A. Messori and F. Moroni. Clinical pharmacokinctics of valproic acid- 1988. Clin. Pharmacokinet., 15, 367-389 (1988).
13. R. H. Levy and D. D. Shen. Valproate - absorption, distribution and excretion. In Antiepileptic Drugs, R. H. Levy. R. H. Mattson and B. S. Meldrum (Eds), Raven. New York, 1995. pp. 605-620.
14. H. Nau, R.-S. Siegbert and K. Ebley, Valproic acid-induced neural tube defect in mouse and humans: aspects of chirality. alternative drug development, pharmacokinetics and possible mechanism. Pharmacol. Toxicol., 69, 310-321 (1991).
15. M. Bialer, Clinical pharmacology of valpromide. Clin. Pharmacokinet., 20, 114-122 (1991).
16. H. Nau and G. Hendrickx, Valproic acid teratogenesis. Atlas Sci. Pharmacol., 52 56 (1987).
17. A. Haj-Yehia and M. Bialer, Structure pharmacokinetic relationships in a series of short fatty acid amides that possess antiepileptic activity. J. Pharm. Sci., 79, 719-724 (1991).
18. A. Haj-Yehia, S. Hadad and M. Bialer, Pharmacokinetic analysis on the structural requirements to form 'stable' analogs of valpromide. Pharm. Res., 8, 750-753 (1992).
19. A. Haj-Yehia, M. Bialer, Pharmacokinctics of valpromide isomer, valnoctamide, in dogs. J. Pharm. Sci., 77, 831-834 (1988).
20. M. Bialer, A. Haj-Yehia, N. Barzaghi, F. Pisani and E. Pcrucca. Pharmacokinetics of valpromide isomer, valnoctamide. in healthy subjects. Eur. J. Clin. Pharmacol., 38. 289-291 (1990).
21. M. Bialer, A. Haj-Yehia, K. Badir and S. Hadad, Can we develop improved derivatives of valproic acid? Pharm. World Sci., 16, 2-6 (1994).
22. R. J. Porter, J. J. Cereghino, G. D. Gladding, B. J. Hessie, H. J. Kupferberg, B. Scoville and B. G. White, Antiepileptic Drug Development Program. Clin. Clin. Q., 51, 293-305 (1984).
23. M. Bialer, M. Friedman and J. Dubrovsky, A rapid GLC assay for monitoring valproic acid and valpromide in plasma. J. Pharm. Sci., 73, 991-992 (1984).
24. M. Gibaldi and D. Perrier, Pharmacokinetics, 2nd edn. Dekker. New York. 1982, pp.445-449.
25. L. Z. Benet and R. L. Galeazzi, Non-compartmental determination of steady-state volume of distribution. J. Pharm. Sci., 68. 1071-1074 (1979).
26. K. Yamaoka, T. Nakagawa and T. Uno, Statistical moments in pharmacokinetics. Pharmacokinet. Biopharm., 6. 547-558 (1978).
27. K. Yamaoka, Methods for Pharmacokinetic Analysis for Personal Computers. 2nd edn. NankoD. Tokyo. 1986. pp. 145-175.